Chiesi Farmaceutici S.p.A.

Chiesi is one of the top 50 pharmaceutical companies globally, with over 90 years of experience transforming patient care through innovative therapeutic solutions. Headquartered in Parma, Italy, this research-oriented international biopharmaceutical group employs more than 8,000 people across 31 countries, united by a singular purpose: promoting a healthier world for people, patients, and the planet. As a family-owned company now in its third generation, Chiesi has developed expertise in respiratory health, neonatology, special care, and rare diseases - touching millions of lives through groundbreaking medicines and treatments.

In 2019, Chiesi became the world's largest pharmaceutical group certified as a B Corp, demonstrating its commitment to meeting high standards of social and environmental performance. The company operates as a Benefit Corporation, embedding sustainability directly into its bylaws and continuously measuring its impact on patients, the planet, and communities. With over €3 billion in global sales and a 10% year-over-year growth, Chiesi has established itself as a leader in biotech innovation, including opening a state-of-the-art Biotech Center of Excellence in 2024. Their pipeline spans lysosomal storage diseases, rare hematology, ophthalmology disorders, and rare immunodeficiencies, ensuring that no patient is left behind.